Squibb Diagnostics' Cardio Tec (Tc 99m teboroxime)
Executive SummaryRadioactive forms of the myocardial perfusion agent will be distributed exclusively by radiopharmacies operator Syncor. Under the agreement, Squibb will sell non-radioactive forms of Cardio Tec to medical centers that perform their own radioactive compounding. Cardiotec was recommended for approval Nov. 17 by the FDA Radiopharmaceutical Committee for use in distinguishing normal from abnormal myocardium in patients with suspected coronary artery disease.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 10)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this tenth and final installment of a 10-part series, the experts explain why it’s important to be honest with investigators at all times.
It hasn’t even happened yet, but Brexit has already had a huge impact on the EU regulatory network and on the life science sector operating in the EU, particularly in the UK. We look back at some of the key events over the past ten years that have woven the UK ever more closely into the EU’s tight-knit regulatory network, and why the UK’s future links with that network will remain uncertain after the country leaves the EU on 31 January.